GlassScriptPhysician profile
Jerry T Davis
NPI 1821179003
$3,028.71
in general payments reported to CMS, 2019-2025
35 companies · $19.24 in 2025
The $19.24 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $640 · 2021: $643 · 2022: $447 · 2023: $202 · 2024: $159 · 2025: $19.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $411.23 | 2019-2022 | |
| Abbvie INC. | $392.16 | 2021-2025 | Botox, Vraylar |
| Amarin Pharma, INC. | $296.67 | 2019-2020 | |
| Glaxosmithkline, LLC. | $288.58 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.73 | 2019-2022 | |
| Genentech USA, INC. | $188.19 | 2019-2022 | |
| Allergan, INC. | $174.59 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $112.25 | 2022 | |
| Janssen Pharmaceuticals, INC | $101.63 | 2019 | |
| Antares Pharma, INC. | $86.81 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $81.53 | 2021 | |
| Galderma Laboratories, L.P. | $78.17 | 2019-2023 | |
| Pfizer INC. | $69.87 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $68.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $55.51 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.24 | 2019-2024 | Wegovy |
| Halozyme INC | $45.03 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.17 | 2022 | |
| Lilly USA, LLC | $31.94 | 2021-2023 | Mounjaro |
| Alfasigma USA, INC. | $27.05 | 2021 | |
| Dusa Pharmaceuticals, INC. | $18.98 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.78 | 2020 | |
| Horizon Therapeutics Plc | $17.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.90 | 2024 | Voquezna |
| Optinose US, INC. | $16.90 | 2020 | |
| Eisai INC. | $16.78 | 2021 | |
| Ibsa Pharma INC. | $16.05 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.33 | 2020 | |
| Mannkind Corporation | $15.11 | 2022 | |
| Si-Bone, INC. | $14.58 | 2020 | |
| Zyla Life Sciences, INC. | $13.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2022 | |
| Azurity Pharmaceuticals, INC. | $12.96 | 2023 | Edarbi |
| Clarus Therapeutics INC. | $12.94 | 2021 | |
| Cranial Technologies, INC | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.